RSS Feeds

Email a Friend Printer Friendly

A new pathway for halting neuronal death in Huntington's disease

June 12, 2002

The body is an extremely complex puzzle in which every piece plays a critical role. Should pieces disappear harmony is compromised. Such is the case with certain neurodegenerative diseases; when neurons suddenly die, the body's ability to function properly is jeopardized.

CNRS (1) and INSERM biologists from the Curie Institute are working to understand how neurons die in one specific neurodegenerative disease: Huntington's disease.
They have just announced the discovery of two new factors capable of blocking cell death induced in Huntington's disease. They may eventually provide targets for the therapeutic treatment of this type of disease.
These discoveries were published in the 7th of June issue of Developmental Cell.

Huntington's disease, also known as Huntington chorea, is a rare neurological disease that affects one in every 10,000 individuals. The disease's most striking symptoms, which are usually manifested between the age of 35 and 50 years, include abnormal and involuntary jerky movements of the limbs, head and neck (chorea). Other symptoms include behavioral problems (anxiety, irritability, depression, etc.). As the disease progresses, a slow intellectual deterioration inevitably leads to dementia. Death occurs between 15 to 20 years after the onset of the disease, usually due to complications (pulmonary emboli, pneumonia, or similar infection).

Clinical diagnosis is often long and difficult to establish due to a wide range of symptoms that can easily be confused with other psychological disorders. Diagnosis should be confirmed by MRI scan of the brain or by genetic testing. If a family history of the disease can be established, predictive gene testing can be done on asymptomatic family members. However, this step must be thoughtfully considered beforehand as the disease's initial symptoms appear relatively late, and at present, there is no treatment that can effectively delay the onset or the development of the disease.

A mutant protein: huntingtin

Huntington's disease is an autosomal dominant genetic disorder: if one of two parents carry the mutant gene, 50% of their offspring will inherit the mutation and develop the disease.
The IT15 gene responsible for the disease, located on chromosome 4, enables the synthesis of the huntingtin protein, whose function has yet to be established. In its normal state, this protein contains repeated tracks of the amino acid glutamine. These repeats can become dangerous: if a threshold of 35 to 40 glutamines is exceeded, huntingtin becomes mutant and induces the disease. The more numerous the repeats, the earlier the symptoms appear.

It has been established that this abnormal expansion of glutamines is responsible for a change in the structure of huntingtin, which by some still poorly understood mechanism provokes neuronal cell death.

A number of other neurodegenerative diseases have also been linked to the same type of mutation. Different, specific regions of the brain are affected in each of these diseases. In Huntington's disease, it is the striatum neurons (implicated in motor control), which gradually degenerate.

Under the direction of Frederic Saudou (2), a research team ("Intracellular signalling and neuronal death" UMR 146 CNRS/Institut Curie) studying Huntington's disease, has focused particular attention on the proteins suspected of playing a role in the neuronal death associated with this disease.

A model to understand neuronal death

To shed light on the mechanisms involved when neuronal death is induced by mutant huntingtin, researchers at the Curie Institute developed a cell model that reproduces the disease's characteristics. The tool had already proved to be ideal as it allowed them to demonstrate that the huntingtin protein had to build up within the nucleus of the cell to induce neuronal death by apoptosis (3) (see "More information").

Using the same tool, Sandrine Humbert (4), a member of Frederic Saudou's team, has just demonstrated that the proteins IGF-1 and Akt (see "More information") have a protective effect in the cellular model that reproduced the pathological symptoms.

Indeed, IGF-1 and Akt are capable of blocking both neuronal death and the formation of intranuclear aggregates within cells where the huntingtin protein is mutant (images available).

The researchers also discovered how the Akt protein "disrupts the plans" of mutant huntingtin: it chemically modifies it (via a mechanism known as phosphorylation), which leads to a change in both form and function. Once the huntingtin protein is altered by Akt, they noticed that aggregates no longer form in the nucleus and that apoptotic death is prevented. It is therefore a chemical modification that nullifies the negative effects of the mutant huntingtin protein inside the cells.

This is the first time factors that have a direct impact on the protein implicated in Huntington's disease have been discovered.
Furthermore, Frederic Saudou's team has demonstrated that the protein Akt has an abnormal appearance in patients suffering from Huntington's disease. This provides further proof, if any were needed, of the role of Akt in the development of this disease.

The IGF-1/Akt signaling pathway: a therapeutic turning point

Although these discoveries are still at a fundamental stage, they already point towards promising new treatments for Huntington's disease. It is conceivable that the IGF-1 or Akt proteins may provide a therapeutic target for "deactivating" apoptosis, thus giving hope to all those afflicted with Huntington's disease.

Eventually, research into treatments for other diseases like cancer, in which apoptosis plays a key role (see "More information"), may also benefit from these discoveries.

Institut Curie